Neuropace Begin Period Cash Flow Over Time
| NPCE Stock | USD 10.20 0.46 4.32% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Neuropace Performance and Neuropace Correlation. Neuropace |
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuropace. If investors know Neuropace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuropace listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.98) | Revenue Per Share 2.697 | Quarterly Revenue Growth 0.282 | Return On Assets (0.15) | Return On Equity (2.15) |
The market value of Neuropace is measured differently than its book value, which is the value of Neuropace that is recorded on the company's balance sheet. Investors also form their own opinion of Neuropace's value that differs from its market value or its book value, called intrinsic value, which is Neuropace's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuropace's market value can be influenced by many factors that don't directly affect Neuropace's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuropace's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuropace is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuropace's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Begin Period Cash Flow Analysis
Compare Neuropace and related stocks such as Electromed, Orthopediatrics Corp, and SurModics Begin Period Cash Flow Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ELMD | 966.7 K | 4.1 M | 1.7 M | 503.6 K | 1.5 M | 3.6 M | 5.1 M | 5.6 M | 7.5 M | 7.8 M | 10.5 M | 11.9 M | 8.2 M | 7.4 M | 5.1 M |
| KIDS | 58 K | 58 K | 58 K | 58 K | 58 K | 6.6 M | 3.9 M | 1.6 M | 42.6 M | 60.7 M | 72 M | 30.1 M | 9 M | 10.5 M | 9.9 M |
| SRDX | 500 K | 23.2 M | 15.5 M | 15.5 M | 43.5 M | 55.6 M | 25 M | 16.5 M | 23.7 M | 30.4 M | 30.8 M | 31.2 M | 19 M | 41.4 M | 43.5 M |
| FNA | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 2.6 M | 17.5 M | 109.4 M | 38.5 M | 37.2 M |
| NVRO | 11.3 M | 11.3 M | 11.3 M | 5.6 M | 12.4 M | 25.3 M | 87 M | 41.4 M | 43.7 M | 51.9 M | 66.3 M | 45.2 M | 35.3 M | 121 M | 127 M |
| ITGR | 4.1 M | 22.9 M | 36.5 M | 20.3 M | 35.5 M | 76.8 M | 82.5 M | 52.1 M | 44.1 M | 25.6 M | 13.5 M | 49.2 M | 17.9 M | 24.3 M | 40.6 M |
| GKOS | 5.6 M | 5.6 M | 5.6 M | 1.7 M | 6.7 M | 2.3 M | 21.6 M | 6.5 M | 24.5 M | 38.6 M | 71.8 M | 106.2 M | 110.1 M | 126.6 M | 132.9 M |
| CNMD | 300 K | 12.4 M | 26 M | 23.7 M | 54.4 M | 66.3 M | 72.5 M | 27.4 M | 32.6 M | 17.5 M | 25.9 M | 27.4 M | 20.8 M | 28.9 M | 18.1 M |
| ANIK | 5.1 M | 28.2 M | 35.8 M | 44.1 M | 63.3 M | 100.2 M | 110.7 M | 104.3 M | 133.3 M | 89 M | 157.5 M | 95.8 M | 94.4 M | 86.3 M | 54.1 M |
| LUNG | 10.1 M | 10.1 M | 10.1 M | 10.1 M | 10.1 M | 10.1 M | 10.1 M | 10.1 M | 10.1 M | 4.1 M | 14.8 M | 231.8 M | 148.7 M | 102 M | 93.8 M |
| IRMD | 593 K | 593 K | 593 K | 1.7 M | 2.5 M | 9.5 M | 19.4 M | 17.7 M | 18.2 M | 28 M | 43.5 M | 50.1 M | 62 M | 58 M | 60.9 M |
| OFIX | 200 K | 13.6 M | 33.2 M | 31.1 M | 28.9 M | 36.8 M | 63.7 M | 39.6 M | 81.2 M | 72.2 M | 70.4 M | 96.8 M | 87.8 M | 50.7 M | 38.6 M |
| CVRX | 9.1 M | 9.1 M | 9.1 M | 9.1 M | 9.1 M | 9.1 M | 9.1 M | 9.1 M | 9.1 M | 9.1 M | 25.7 M | 59.1 M | 142.1 M | 106.2 M | 75.3 M |
| AORT | 100 K | 35.5 M | 21.7 M | 13 M | 37.6 M | 33.4 M | 37.6 M | 56.6 M | 40.8 M | 42.2 M | 34.3 M | 62 M | 55 M | 39.4 M | 21.8 M |
Neuropace and related stocks such as Electromed, Orthopediatrics Corp, and SurModics Begin Period Cash Flow description
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.My Equities
My Current Equities and Potential Positions
| Neuropace | NPCE |
Specialization | Health Care, Health Care Equipment & Services |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 10.2
Check out Neuropace Performance and Neuropace Correlation. For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Neuropace technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.